Quantification of concordance and discordance between apolipoprotein-B and the currently recommended non-HDL-cholesterol goals for cardiovascular risk assessment in patients with diabetes and hypertriglyceridemia.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Author(s): Ganda OP;Ganda OP; Jumes CG; Abrahamson MJ; Molla M
  • Source:
    Diabetes research and clinical practice [Diabetes Res Clin Pract] 2012 Jul; Vol. 97 (1), pp. 51-6. Date of Electronic Publication: 2012 Mar 28.
  • Publication Type:
    Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • Language:
    English
  • Additional Information
    • Source:
      Publisher: Elsevier Scientific Publishers Country of Publication: Ireland NLM ID: 8508335 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1872-8227 (Electronic) Linking ISSN: 01688227 NLM ISO Abbreviation: Diabetes Res Clin Pract Subsets: MEDLINE
    • Publication Information:
      Publication: 1993- : Limerick : Elsevier Scientific Publishers
      Original Publication: Amsterdam : Elsevier Science Publishers B.V., c1985-
    • Subject Terms:
      Apolipoproteins B/*blood ; Cholesterol, LDL/*blood ; Diabetes Mellitus, Type 1/*blood ; Diabetes Mellitus, Type 2/*blood ; Diabetic Angiopathies/*blood ; Hypertriglyceridemia/*blood; Diabetes Mellitus, Type 1/complications ; Diabetes Mellitus, Type 2/complications ; Diabetic Angiopathies/physiopathology ; Female ; Humans ; Hypertriglyceridemia/physiopathology ; Male ; Middle Aged ; Nutrition Surveys ; Risk Assessment ; Sex Distribution ; United States
    • Abstract:
      Aims: In patients with diabetes and hypertriglyceridemia, LDL-cholesterol (LDL-C) provides an inaccurate reflection of LDL particle burden. The relative value of non-HDL-cholesterol (non-HDL-C) and apolipoprotein-B (Apo-B) in estimating cardiovascular risk is controversial. We assessed the discordance between non-HDL-C and Apo-B targets in patients with diabetes with TG 200-499 mg/dl.
      Methods: Data from 1430 determinations of LDL-C, non-HDL-C, and Apo-B in ambulatory patients with diabetes were analyzed. Rates of discordance were calculated, based on the currently recommended LDL-C, non-HDL-C, and Apo-B goals.
      Results: In patients with non-HDL-C goal of <130 mg/dl, there was a discordance with Apo-B level goal of <90 mg/dl, in 31% of samples. In patients with non-HDL-C goal of <100 mg/dl, 6% of samples had Apo-B ≥80 and 18% had Apo-B <80 mg/dl. Using the Apo-B goal of <70 mg/dl, these numbers were 37% and 3.5% respectively. There was also a significant gender difference, i.e. under-estimation of risk by suggested non-HDL-C cut-offs, in females, compared to males.
      Conclusions: In patients with diabetes and hypertriglyceridemia, a considerable discordance exists between non-HDL-C and Apo-B. Our data suggest a need for prospective studies to compare the relative merits of non-HDL-C and Apo-B targets in the assessment of cardiovascular risk.
      (Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.)
    • References:
      Arch Intern Med. 2009 Mar 23;169(6):572-8. (PMID: 19307519)
      JAMA. 2009 Nov 18;302(19):2104-10. (PMID: 19920234)
      N Engl J Med. 2010 Apr 29;362(17):1563-74. (PMID: 20228404)
      N Engl J Med. 2011 Dec 15;365(24):2255-67. (PMID: 22085343)
      Circulation. 2011 May 24;123(20):2292-333. (PMID: 21502576)
      Lancet. 2001 Dec 15;358(9298):2026-33. (PMID: 11755609)
      JAMA. 2001 May 16;285(19):2486-97. (PMID: 11368702)
      Diabetes Care. 2006 Mar;29(3):531-7. (PMID: 16505501)
      J Clin Lipidol. 2011 Sep-Oct;5(5):338-67. (PMID: 21981835)
      Cardiovasc Diabetol. 2011 Feb 28;10:20. (PMID: 21356116)
      J Am Coll Cardiol. 2004 Aug 4;44(3):720-32. (PMID: 15358046)
      JAMA. 2009 Nov 11;302(18):1993-2000. (PMID: 19903920)
      Am J Cardiol. 2003 May 15;91(10):1173-7. (PMID: 12745098)
      Can J Cardiol. 2009 Oct;25(10):567-79. (PMID: 19812802)
      Diabetologia. 2010 Sep;53(9):1846-55. (PMID: 20526762)
      Endocr Pract. 2009 May-Jun;15(4):370-6. (PMID: 19454383)
      Lancet. 2008 Jul 19;372(9634):224-33. (PMID: 18640459)
      Clin Chem. 1994 Apr;40(4):586-92. (PMID: 8149615)
      Clin Chem. 2009 Mar;55(3):407-19. (PMID: 19168552)
      Diabetes. 2008 Dec;57(12):3289-96. (PMID: 18809621)
      J Intern Med. 2006 Mar;259(3):247-58. (PMID: 16476102)
      Diabetes Care. 2008 Apr;31(4):811-22. (PMID: 18375431)
      Circ Cardiovasc Qual Outcomes. 2011 May;4(3):337-45. (PMID: 21487090)
      Biometrics. 1977 Mar;33(1):159-74. (PMID: 843571)
      Diabetes Care. 2009 Jun;32(6):1087-91. (PMID: 19265025)
      Mayo Clin Proc. 2010 May;85(5):446-50. (PMID: 20435838)
      J Am Coll Cardiol. 2008 Aug 19;52(8):626-32. (PMID: 18702965)
      J Clin Lipidol. 2010 Mar-Apr;4(2):83-8. (PMID: 21122634)
    • Grant Information:
      P30 DK036836 United States DK NIDDK NIH HHS; P30DK36836 United States DK NIDDK NIH HHS
    • Accession Number:
      0 (Apolipoproteins B)
      0 (Cholesterol, LDL)
    • Publication Date:
      Date Created: 20120331 Date Completed: 20121204 Latest Revision: 20211021
    • Publication Date:
      20240628
    • Accession Number:
      PMC3758365
    • Accession Number:
      10.1016/j.diabres.2012.02.013
    • Accession Number:
      22459987